Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05505916 · ClinicalTrials.gov registry record · Phase 3
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
A Phase 3 study of Hereditary Angioedema, sponsored by KalVista Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 145
- Enrollment target
- 20
- Study locations
NCT05505916 is a Phase 3 study of Hereditary Angioedema that is active but no longer recruiting, run by KalVista Pharmaceuticals. The registered enrollment target is 145 participants, above the 65-participant average among 14 other Hereditary Angioedema trials with a reported enrollment target (123% higher). The trial reports 20 study locations across 16 states.
The verdict
NCT05505916, a Phase 3 study of Hereditary Angioedema, is active but no longer recruiting, sponsored by KalVista Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 145 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label, multicenter extension trial to evaluate the long-term safety of KVD900 in patients who are 12 years or older with HAE type I or II.
Conditions Studied
Interventions
- DRUG KVD900 600 mg
- DRUG KVD900 300 mg
Study Locations (20)
California
- KalVista Investigative Site - San Diego
- KalVista Investigative Site - San Diego
- KalVista Investigative Site - Santa Monica
Colorado
- KalVista Investigative Site - Centennial
- KalVista Investigative Site - Colorado Springs
Ohio
- KalVista Investigative Site - Cincinnati
- KalVista Investigative Site - Toledo
Arizona
- KalVista Investigative Site - Scottsdale
Arkansas
- KalVista Investigative Site - Little Rock
Indiana
- KalVista Investigative Site - Evansville
Kansas
- KalVista Investigative Site - Overland Park
Kentucky
- KalVista Investigative Site - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2022-10-24 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05505916
The ClinicalTrials.gov registry entry for NCT05505916 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 145 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 65-participant average among 14 other Hereditary Angioedema trials with a reported enrollment target (123% higher). The listed sponsor is KalVista Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hereditary Angioedema appearing as the primary indexed condition, and to 2 interventions - of which KVD900 600 mg is the first listed.
NCT05505916 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, Colorado, Ohio.
Frequently Asked Questions
What is clinical trial NCT05505916 about?
NCT05505916 is a clinical study titled "An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)". This is an open-label, multicenter extension trial to evaluate the long-term safety of KVD900 in patients who are 12 years or older with HAE type I or II.
What is the current status of trial NCT05505916?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 145 participants. The study started on 2022-10-24. Estimated completion is 2026-06-30.
What conditions does trial NCT05505916 study?
This clinical trial studies the following conditions: Hereditary Angioedema.
What interventions are being tested in trial NCT05505916?
The interventions under investigation include: KVD900 600 mg (DRUG), KVD900 300 mg (DRUG).
Who is sponsoring clinical trial NCT05505916?
This trial is sponsored by KalVista Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05505916 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hereditary Angioedema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
RECRUITING · Phase 3
-
A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)
ACTIVE NOT RECRUITING · Phase 3
-
HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)
ACTIVE NOT RECRUITING · Phase 3
-
PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial
ACTIVE NOT RECRUITING · Phase 3
-
Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks
COMPLETED · Phase 3
-
OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.